PubRank

Christian Kurzeder

Author PubWeight™ 34.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011 8.63
2 Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 2013 1.36
3 Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients. Breast 2010 1.15
4 Bevacizumab in the treatment of ovarian cancer. Adv Ther 2012 1.12
5 Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010 1.11
6 Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011 1.09
7 Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett 2008 0.96
8 Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 2003 0.95
9 Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002 0.92
10 Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2010 0.92
11 Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie 2010 0.91
12 Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol 2013 0.89
13 Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer 2014 0.88
14 Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep 2003 0.87
15 Pretreatment staging of cervical cancer: is imaging better than palpation?: Role of CT and MRI in preoperative staging of cervical cancer: single institution results for 255 patients. Ann Surg Oncol 2008 0.86
16 Partial breast irradiation after breast-conserving surgery. Strahlenther Onkol 2005 0.85
17 High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors. Exp Hematol 2003 0.85
18 Focus on haematogenous dissemination of the malignant cystosarcoma phylloides: institutional experience. Arch Gynecol Obstet 2010 0.85
19 Immunotherapy and cancer vaccines in the management of breast cancer. Curr Pharm Des 2005 0.84
20 CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002 0.84
21 Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. Int J Gynecol Cancer 2016 0.82
22 Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer 2014 0.79
23 Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Arch Gynecol Obstet 2010 0.79
24 Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs 2013 0.78
25 Prognostic impact of satellite-lymphovascular space involvement in early-stage cervical cancer. Ann Surg Oncol 2008 0.78
26 New molecular targets of breast cancer therapy. Strahlenther Onkol 2002 0.77
27 Implementation of robot-assisted gynecologic surgery for patients with low and high BMI in a German gynecological cancer center. Arch Gynecol Obstet 2014 0.77
28 Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. Int J Oncol 2005 0.77
29 Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol 2006 0.77
30 Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy? Strahlenther Onkol 2007 0.77
31 Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. Int J Gynecol Cancer 2017 0.77
32 Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective. ISRN Oncol 2011 0.76
33 B-cell-specific elements enhance sustained gene expression mediated by self-replicating extrachromosomal vectors. Mol Med Rep 2011 0.76
34 Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). Int J Gynecol Cancer 2016 0.75
35 Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. Int J Gynecol Cancer 2016 0.75
36 Surgery for recurrent ovarian cancer. Womens Health (Lond Engl) 2011 0.75